This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sales Disclosure Pummels aaiPharma

Updated from 11:22 a.m. EST

Shares of aaiPharma (AAII) were pounded Monday following the company's announcement it had detected "unsual sales" in two product lines during the second half of 2003.

At the close, the drugmaker's stock was off $5.52, or 36.1%, to $9.76, having closed at $31.50 just six weeks ago.

As a consequence of this discovery, the Wilmington, N.C.-based company withdrew financial guidance for the first quarter and full-year 2004, saying the irregularities would "materially affect" previous financial estimates.

It also said it may have to make "an adjustment in the 2003 financial results" depending on the results of an investigation by a group of independent directors and an outside law firm.

Previously, the company had predicted first-quarter 2004 earnings of 27 cents to 30 cents a share and full-year EPS of $1.45 to $1.52. The company had also forecast full-year sales in the range of $340 million to $355 million.

Monday's announcement prompted two investment banking firms to cut their ratings, and Moody's Investor Service said it had placed the company's debt under review for a possible downgrade.

The company's investigation concerns the sales of Darvocet, a painkiller, and Brethine, a treatment for the wheezing and lung discomfort associated with asthma, emphysema and bronchitis. The company said the problems came to light after it had released its 2003 financial report Feb. 5.

"The company will not comment further on these matters until the independent inquiry has been concluded and the results of the inquiry have been publicly reported," said Dr. Frederick D. Sancillo, aaiPharma's chairman, in a prepared statement.

Even if the internal review doesn't lead to restating earnings, "management credibility has been significantly diminished," said Elliott Wilbur, of CIBC World Markets, in a research report Monday. He cut his rating to sector underperformer from sector performer. (He doesn't own shares; his firm is a market maker, and it expects to receive or intends to seek compensation for investment banking services in the next three months.)

Banc of America Securities cut its 12-month price target to $13.50 from $30 and reduced its rating on the stock to neutral from buy. Analyst David W. Maris told clients Monday that he still liked the company's long-term prospects, but worried about "the uncertainty surrounding an ongoing internal review of inventory levels and the change this uncertainty represents." (He doesn't own shares; his firm is a market maker for aaiPharma and has performed investment banking services for the company in the last 12 months).

Monday's announcement is another in a series of recent setbacks that have eroded aaiPharma's stock recently. Several analysts have expressed concern that aaiPharma has too many products sitting for too long in drug wholesalers' warehouses, imperiling the quality of the company's reported sales and earnings. Others say its debt level is too high for the drug industry.

Three weeks ago, aaiPharma announced it had set aside a $15.9 million reserve against revenue in the fourth quarter of 2003 to account for products that are returned. One of those products was Brethine, whose returns, the company said, were "significantly greater" in the fourth quarter than in any other quarter. When it announced the reserve, company executives said they were comfortable with inventory levels among wholesalers.

Just after aaiPharma announced creation of the reserve and made forecasts for 2004, it reported that its chief operating officer, David M. Hurley, was leaving to become president of a start-up drug company. Hurley had been with aaiPharma for two years and had held the COO job for only five weeks.

In recent weeks, at least eight shareholder lawsuits have been filed against the company. They allege, as one complaint puts it, that the company engaged in securities fraud by issuing "materially false and misleading" financial statements between April 24, 2002 and Feb. 4, 2004 , "artificially inflating [the] market price."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
YHOO $30.96 0.34%
AAPL $111.97 1.10%
FB $93.35 -0.70%
GOOG $649.00 1.20%
TSLA $241.46 -1.91%


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs